Literature DB >> 12548548

Cancer/testis-associated genes: identification, expression profile, and putative function.

Albert J W Zendman1, Dirk J Ruiter, Goos N P Van Muijen.   

Abstract

Cancer/testis-associated genes (CTAs) are a subgroup of tumor antigens with a restricted expression in testis and malignancies. During the last decade, many of these immunotherapy candidate genes have been discovered using various approaches. Most of these genes are localized on the X-chromosome, often as multigene families. Methylation status seems to be the main, but not the only regulator of their specific expression pattern. In testis, CTAs are exclusively present in cells of the germ cell lineage, though there is a lot of variation in the moment of expression during different stages of sperm development. Likewise, there is also a lot of heterogeneity in the expression of CTAs in melanoma samples. Clues regarding functionality of CTAs for many of these proteins point to a role in cell cycle regulation or transcriptional control. Better insights in the function of these genes may shed light on the link between spermatogenesis and tumor growth and could be of use in anti-tumor therapies. This review outlines the CTA family and focuses on their expression and putative function during male germ cell development and melanocytic tumor progression. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548548     DOI: 10.1002/jcp.10215

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  62 in total

1.  Inverted repeat structure of the human genome: the X-chromosome contains a preponderance of large, highly homologous inverted repeats that contain testes genes.

Authors:  Peter E Warburton; Joti Giordano; Fanny Cheung; Yefgeniy Gelfand; Gary Benson
Journal:  Genome Res       Date:  2004-10       Impact factor: 9.043

2.  Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients.

Authors:  Raphael B Parmigiani; Fabiana Bettoni; Maria D Vibranovski; Marilene H Lopes; Waleska K Martins; Isabela W Cunha; Fernando A Soares; Andrew J G Simpson; Sandro J de Souza; Anamaria A Camargo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

Review 3.  Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.

Authors:  Yan-Ho Cheng; Elissa Wp Wong; C Yan Cheng
Journal:  Spermatogenesis       Date:  2011-07-01

Review 4.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 5.  Selfish genetic elements and sexual selection: their impact on male fertility.

Authors:  Tom A R Price; Nina Wedell
Journal:  Genetica       Date:  2008-03-08       Impact factor: 1.082

Review 6.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

7.  Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status.

Authors:  Luca Sigalotti; Alessia Covre; Susan Zabierowski; Benjamin Himes; Francesca Colizzi; Pier Giorgio Natali; Meenhard Herlyn; Michele Maio
Journal:  J Cell Physiol       Date:  2008-05       Impact factor: 6.384

8.  The SPANX gene family of cancer/testis-specific antigens: rapid evolution and amplification in African great apes and hominids.

Authors:  Natalay Kouprina; Michael Mullokandov; Igor B Rogozin; N Keith Collins; Greg Solomon; John Otstot; John I Risinger; Eugene V Koonin; J Carl Barrett; Vladimir Larionov
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

Review 9.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  Clin Dev Immunol       Date:  2010-10-11

10.  Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers.

Authors:  Jan Rohozinski; Matthew L Anderson; Russell E Broaddus; Creighton L Edwards; Colin E Bishop
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.